Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Agricultural biotech firm hired a site-selection consultant and considered other cities around the world for its $340 million
expansion.
The investment will greatly expand the company’s research and development capacity and is a major win for the Indiana
life sciences industry. Dow AgroSciences expects most of the positions to pay between $65,000 and $95,000 annually.
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Local Dow Chemical subsidiary expects to launch five new biotech products by 2012.
Greenfield Labs operation expects to add 17 Eli Lilly and Co. workers after taking over staff of 264 in 2008 acquisition.
The firms continued to grow over the last year but face increasing challenges, according to a new report by Indianapolis-based
life sciences trade group BioCrossroads.
Indianapolis-based Vortek Surgical LLC will relocate to Brownsburg, expanding its headquarters, manufacturing and distribution
operations and creating more than 60 jobs in the next three years.
Bioanalytical Systems Inc., a West Lafayette-based life sciences contract research firm, on Wednesday reported a loss of $1.4
million for its fiscal first quarter.
Dow AgroSciences CEO Antonio Galindez told investors Wednesday morning that the company plans to launch five products
by 2013 that could increase annual revenue by $800 million.
A report set to be released Wednesday by local life sciences industry group BioCrossroads says Indiana companies providing
contract pharmaceutical research and manufacturing services are weathering the economic downturn and are growing.
The Indianapolis area is home to myriad unsung entrepreneurs who run interesting companies, make money and create good jobs.
Here are some of them.
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
An Indiana University prof thinks Indianapolis should anticipate a future without Indianapolis Motor Speedway, and a potentially
reduced Eli Lilly and Co.
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009. That trend hit Indianapolis,
but the rest of the state actually saw an increase.
Indianapolis-based Dow AgroSciences said Tuesday it posted a profit of $69 million in the fourth quarter, down 19 percent
from the prior year because of increased research and development spending and higher administrative expenses. Revenue was
up 17 percent.
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
The awards are meant to showcase Indiana’s high-tech success stories and raise the profile of the tech community.
Indianapolis-based Dow AgroSciences LLC has sued Cooper Industries Plc in an effort to clarify its rights to make a canola-based
fluid used in electrical transformers.
